Heparin (Lithium) for Interference Testing

<strong>Heparin for Interference Testing</strong>_x000D_ <strong>Catalog number:</strong> B2010201_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Volume/Weight:</strong> 2500 U at &gt; 150 U/mg_x000D_ <strong>pH:</strong> na_x000D_ <strong>Supplied as:</strong> Ready-to-use_x000D_ <strong>Appearance:</strong> Powder_x000D_ <strong>Applications:</strong> highly pure Lithium Heparin (&gt;150 U/mg) that can be spiked in specimen to test Lithium Heparin interference in various assays._x000D_ <strong>Storage:</strong> RT_x000D_ <strong>Keywords:</strong> Heparin lithium salt, Li-heparin_x000D_ <strong>Grade:</strong> Biotechnology grade. All components are highly pure (minimum 99%). All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered on a 0.22 um._x000D_ <h4><strong>All Interference Products Brochure_x000D_ </strong></h4>_x000D_ <a href="https://moleculardepot.com/wp-content/uploads/2022/05/MKT-003-Interference-Testing-Brochure-Rev.-B.pdf"><img class="alignnone wp-image-233791479" src="https://moleculardepot.com/wp-content/uploads/2020/08/Interference-Testing-Brochure-Picture-243x300.png" alt="Interference Testing Brochure" width="252" height="311" /></a>_x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Bolten SN, Rinas U, Scheper T. Heparin: role in protein purification and_x000D_ substitution with animal-component free material. Appl Microbiol Biotechnol._x000D_ 2018 Oct;102(20):8647-8660._x000D_ _x000D_ 2: Cassinelli G, Naggi A. Old and new applications of non-anticoagulant heparin._x000D_ Int J Cardiol. 2016 Jun;212 Suppl 1:S14-21._x000D_ _x000D_ 3: Liu X, St Ange K, Wang X, Lin L, Zhang F, Chi L, Linhardt RJ. Parent heparin_x000D_ and daughter LMW heparin correlation analysis using LC-MS and NMR. Anal Chim_x000D_ Acta. 2017 Apr 8;961:91-99._x000D_ _x000D_ 4: Tyrrell DJ, Horne AP, Holme KR, Preuss JM, Page CP. Heparin in inflammation:_x000D_ potential therapeutic applications beyond anticoagulation. Adv Pharmacol._x000D_ 1999;46:151-208._x000D_ _x000D_ 5: Masuko S, Linhardt RJ. Chemoenzymatic synthesis of the next generation of_x000D_ ultralow MW heparin therapeutics. Future Med Chem. 2012 Mar;4(3):289-96._x000D_ _x000D_ 6: Bertini S, Fareed J, Madaschi L, Risi G, Torri G, Naggi A. Characterization_x000D_ of PF4-Heparin Complexes by Photon Correlation Spectroscopy and Zeta Potential._x000D_ Clin Appl Thromb Hemost. 2017 Oct;23(7):725-734._x000D_ _x000D_ 7: Walenga JM, Lyman GH. Evolution of heparin anticoagulants to ultra-low-_x000D_ molecular-weight heparins: a review of pharmacologic and clinical differences_x000D_ and applications in patients with cancer. Crit Rev Oncol Hematol. 2013_x000D_ Oct;88(1):1-18._x000D_ _x000D_ 8: Bick RL, Frenkel EP, Walenga J, Fareed J, Hoppensteadt DA. Unfractionated_x000D_ heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of_x000D_ actions, pharmacology, and clinical use. Hematol Oncol Clin North Am. 2005_x000D_ Feb;19(1):1-51, v._x000D_ _x000D_ 9: Ouyang Y, Zeng Y, Yi L, Tang H, Li D, Linhardt RJ, Zhang Z. Qualitative and_x000D_ quantitative analysis of heparin and low molecular weight heparins using size_x000D_ exclusion chromatography with multiple angle laser scattering/refractive index_x000D_ and inductively coupled plasma/mass spectrometry detectors. J Chromatogr A. 2017_x000D_ Nov 3;1522:56-61._x000D_ _x000D_ 10: Hull RD, Pineo GF, Stein P. Heparin and low-molecular-weight heparin therapy_x000D_ for venous thromboembolism. The twilight of anticoagulant monitoring. Int_x000D_ Angiol. 1998 Dec;17(4):213-24._x000D_ _x000D_ 11: Xiao Z, Tappen BR, Ly M, Zhao W, Canova LP, Guan H, Linhardt RJ. Heparin_x000D_ mapping using heparin lyases and the generation of a novel low molecular weight_x000D_ heparin. J Med Chem. 2011 Jan 27;54(2):603-10._x000D_ _x000D_ 12: Padma V, Fisher M, Moonis M. Role of heparin and low-molecular-weight_x000D_ heparins in the management of acute ischemic stroke. Expert Rev Cardiovasc Ther._x000D_ 2006 May;4(3):405-15._x000D_ _x000D_ 13: Li G, Yang B, Li L, Zhang F, Xue C, Linhardt RJ. Analysis of 3-O-sulfo_x000D_ group-containing heparin tetrasaccharides in heparin by liquid chromatography-_x000D_ mass spectrometry. Anal Biochem. 2014 Jun 15;455:3-9._x000D_ _x000D_ 14: Kalathottukaren MT, Abbina S, Yu K, Shenoi RA, Creagh AL, Haynes C,_x000D_ Kizhakkedathu JN. A Polymer Therapeutic Having Universal Heparin Reversal_x000D_ Activity: Molecular Design and Functional Mechanism. <a href="https://pubmed.ncbi.nlm.nih.gov/28880550/">Biomacromolecules</a>. 2017 Oct_x000D_ 9;18(10):3343-3358._x000D_ _x000D_ <strong>Products Related to Heparin for Interference Testing </strong> <a>: Biochemical Buffers and Solutions</a>